Company Profile
Sanofi
— A pharmaceutical company built around antibodies and vaccines, adding mRNA, nanobodies, and siRNA through acquisitions and licensing
Sanofi (Sanofi) is a French pharmaceutical company with a sales of €436 billion in 202536% antibody drug Dupixent(Joint development with Regeneron) is occupied (cal。ating this article). In terms of drug discovery and DDS, the characteristics of this company areWidth of modalities[Contact Us Ablynx, which acquired Translate Bio for mRNA in 2021, also acquired nanobody (small antibody fragments) from that year. In 2025, siRNA medicine Qfitlia, using Alnylam technology, was approved in the United States. The pipeline includes mRNA vaccines, nanobodies, AAV gene therapies, and ADCs. In this article, the size of the company is concise,]How do you take the modalities from where you want to make them?Filter by
- Sanofi in 30 seconds and standing position in drug discovery and DDS
- About logo and company name
- Where is this company in the world of drug discovery and DDS?
- Company Size (Concise)
- Drug discovery and DDS resources
- Past Initiatives
- Future plans
- What is DDS?
- Collaboration mapping of drug discovery and DDS
- Technologies, Products and Services
- The risk of this company
- Glossary/Source/Ins ment and Source Response Table
1. Sanofi in 30 seconds and standing position in drug discovery and DDS
Nasdaq: SNY（ADS）Trading with Deposited Securities in the United States
Vac sExpanded to mRNA, nanobody and siRNA
SanofiPharmaceutical Company20-F is a biopharmaceu company that uses AI by R&D. “Utilizing a wide range of technology and manufacturing platforms including mRNA” FactsHome However, most of the technologyNot only those raised from scratch, but those imported by acquisition and introductionComment Nanobody is Ablynx (2018), mRNA is Translate Bio (2021), siRNA is introduced from Alnylam (Qfitlia), Sales pillar antibody Dupixent is jointly developed with Regeneron. When looking at this company in drug discovery and DDS,“Where did you have any technology?”When you press the image, you can see the whole image.
2. Logo and company name
Sano Fino is a trademark of the company. In this article, we do not reproduce the generated image,
Logo on the company's official website (SVG)Home img/sanofi_logo.svg Contact Us
Note: Corporate name Sanofi(F) The former name of the vac business was 'Sanofi ur', and it has now been changed to 'Sanofi R&D Vaccins'. In 2025, we sold Opella's vaccine nature (50.0 CD to CD&R. Please refer to the figures in this article mainly for the pharmaceutical and vac business. Sanofi Corporation
Official Site:https://www.sanofi.com/en3. Where is this company in the world of drug discovery and DDS?
The center of the current sales isMono nal Antibody(Dupixent, Beyfortus, Sarclisa, etc.)Vac s、Proteins such as insulinHome FactsHome HomeNanobody(Cabl), Inc.),Fc Fusion Protein（ALTUVIIIO）、siRNA（Qfitlia）、 mRNA vac m(RSV, hMPV, )H5, clamino, acne, etc.)AAV Therapy、ADC(CEACAM5 target) is added. The mechanism of each technology is handled by the technical commentary of this series: antibody medicine and ADC, mRNA, lipid nanoparticles, nucleic acid drugs, and virus vectors.
4. Company Scope (Concise)
Press only the scale of the company. The amount is Euro (Millions), and the accounting year is calendar year Facts。
| Index | FY2024 | FY2025 | January to June 2026 |
|---|---|---|---|
| Sales (€ million) | 41,081 | 43,626 | 22,106 |
| Dupixent | ― | 15,714 | 9,324 |
| R&D expenses (€ million) | 7,394 | 7,842 | 3,980 |
| Investment in tangible fixed assets (€ million) | ― | 1,822 | 882 |
| (year-end, person) | 82,878 | 74,846 | ― |
The number of employees in 2024 is calculated from the 20-F of "2025 is less than 8,032 people from the previous year". 。ulation of this article). "-" indicates that there is no value of the same category in the document confirmed in this article.
Dupixent on sales of 2025About 36.0% The calculation of this paperHome DupixentCollaboration with RegeneronIt is a mechanism that divides profit based on the arrangement of both companies. FactsHome Research and development costs for modalities (mRNA, nanobody, siRNA, etc.) are not disclosed Undetermined / FutureHome Please read the scale of the company and the scale of each new technology as a separate article.
5. Drug discovery and DDS resources
| Resource Types | ||
|---|---|---|
| Research | engaged in research and development9,274 people(12ulation of this article by 12.4% of all employees at the end of 2025) | Facts |
| Person (Manufacturing base) | Biopharmaceu manufacturing base (hub)Paris, Lyon, Frankfurt, Heel (Be)ium), Boston4 places. Production of cells, microorganisms, and viral vectors | Facts |
| Gold (R&D) | R&D costs €7,842 million (2025, 18.0% of sales) | Facts |
| Gold (Manufacturing Equipment) | Investment in tangible fixed assets €1,822 million (2025). Expect annual average of € 1.75 billion in the middle term. Defined contract for future capital investment is €926 million | Facts |
| Vac Plant | “Evolutive Facility” in Nuville-Sur-Sone, France, a new plant for new vac)s in Singapore, announced in 2020-2021 | Facts |
| Ablynx (nanobody, 2018), Translate Bio (mRNA, 2021, $38), Blueprint (2025, $91 billion share value), Vigil・Vicebio (2025), Dynavax (completed in February 2026) | Facts | |
| License | Alnylam (Qfitlia), VisiRNA (China’s right in Prozaciran), ADEL (ADEL-Y01), Liberty Bio (Gusacitinib), Dren Bio (DR-0201), etc. | Facts |
| AI | Formation Bio and OpenAI jointly developed AI software for pharmaceutical development (May 2024). AI "P " in-house is used by about 22,000 people, and AI "SimpLY" that optimizes yield of manufacturing | Facts |
| Public Funds | In the early clinical trial of the H5 vaccine candidate for pandemic (SP0335), when funded from BARDA in the United States, it is described in 20-F. | Facts |
| Collaboration with universities and research institutions | d primary materials do not include joint research with individual universities on drug discovery and DDS | Not confirmed |
6. Past Initiatives
| Time | Home | The meaning of drug discovery and DDS |
|---|---|---|
| Year 2017 | Contract with AstraZeneca and Beyfortus Development and manufacturing led by AstraZeneca | Long-acting antibodies are acquired in the form of delegation to the other party |
| Mid 2018 | Ablynxunder the umbrella. Nanobody Cabbl approved in the US in September 2018, February 2019 | The technical foundation for small antibody fragments (VHH) is developed. |
| September 14, 2021 | Translate BioCompleted acquisition ($38 per share) | Center of Excellence Both vac s and the eutic drugs are intended |
| February 2023 | FDA approved AL IIIO (Fc, VWF, XTEN Phase VIII factor) | Add an array to the protein and extend the time to stay in the blood, |
| May 2024 | Formation Bio and OpenAI | Introduction of AI for development work |
| March 28, 2025 | FDAQfitliaApprove (U.S. & New Approval) | siRNA using Alnylam’s ESC-GalNAc binding technology. 1 subcutaneous injection per 2 months |
| July 18, 2025 | Blueprint MedicinesCompleted acquisition ($129 per share) | )ed development of pet in)tors (low)s) and immunospheres |
| 2025 years | Acquisition of Vigil (oral low-。 TREM2 actuator) and Vicebio (subunit vac。 of RSV and hMPV). Reduced €1,663 million in Trebrutinib, subject to PERSEUS trial results | Reinforcement of nerve and vac and loss of development failure |
| February 10, 2026 | DynavaxCompleted acquisition of | B-type hepatitis vac B HEPL to obtain V-B. |
| June to July 2026 | Sarclisa of subcutaneous injection formulation (approved in June, USA) | Transformation from drip to subcutaneous injection |
Major clinical trials (Qfitlia approval basis)
| Test name (NCT number) | Phase | Main evaluation items | Information published (comparison contrast/point) |
|---|---|---|---|
| ATLAS-INH（NCT03417102）、ATLAS-A/B（NCT03417245） | Phase 3. Hemophilia A・B | Annual bleeding rate (ABR) | "Clinical meaningful bleeding suppression". The effect of the dose adjustment method (AT-DR) for approval is evaluated in comparison with the contrast data of the continuous test ATLAS-OLE. |
| ATLAS-OLE（NCT03754790） | Phase 3, Single-arm and Non-Blind Test | Safety and efficacy | Contact Us Evaluate dosage adjustments to keep anti-tronbin 15-35% Undetermined / Future |
The specific number of the annual bleeding rate does not include the range that the primary material was confirmed in this article. This article does not recommend a specific drug, but does not inferior to other drugs. Please contact your doctor for treatment.
7. Future plans
Phase 1-2Not confirmed when approved
In the pipeline, mRNA vaccineRSV+hMPV (Aged, Phase 2)、H5 Pandemic (Phase 2)、Acne (Phase 2)、Clamydia (Phase 1)、RSV+hMPV+PIV3(Phase 1)Close FactsHome In the nanobody, the septic sweat gland is phase 2 with phase 3, asthma, phase 2, and bebekimig (targeted by TNFα and OX40L). Both approval periods Undetermined / Future Comment
None of the following documents have been listed Undetermined / Future。
Used for mRNA vaccineComposition and source of lipid nanoparticles (LNP)/Evolutive FacilityProduction capacityHomeOperation status/ MoreR&D expenses/mRNA vaccineApplication period。
8. What is this company aiming for drug discovery and DDS?
This includes parts that the company does not directly state.Calculation in the range that can be read from primary informationand write with the basis.
| Read | Primary Information | |
|---|---|---|
| In the immune area"T targets with one molecule"I want to make the nanobody to the next pillar | Both sekimig (IL-13×TSLP) and bebekimig (TNFα×OX40L) are double-targeted nanobodies, and sekimig is phase 3 with COPD. | |
| mRNAVac sFor practical use | All mRNA items in the are vac s. 20-F is also described as mRNA in the initial stage technology and risk factors | |
| Patient burdenNumber of doses and routesDirections to reduce | Qfitlia (one subcutaneous injection in two months), ALIIIIIIO (once a week), Sarclisa subcutaneous injection preparation, Beyfortus (long-acting antibody) | Facts |
| New technologyFaster acquisition and introduction than your own research | 4 acquisitions and multiple acquisitions in 2025 20-F clearly indicates risks that the acquisition does not produce expected outcomes | |
| AINot only drug discovery but also manufacturing yieldAlso used | The company estimates that SimpLY optimizes the production yield, analyzes over 13,000 b of anticoagulants and leads to a reduction of approximately €10 million per year | Facts |
2025 pipeline change table of 20-F, the newly added item is Blueprint (twoIT in、tors), Dren Bio (CD20 double-specific antibody), Vigil (TREM2 activator), and Spicebio (two vac、s).All come from the acquisition destination FactsHome On the other hand, mRNA has been considered to be a risk factor for the acquisition of Translate Bio for more than four years since the acquisition of Translate Bio in 2021. From here, Sanofi isWhile growing new modalities (mRNAs) that take time to produce results, short-term growth is to buy and supplement items in the latter stageThis article reads that it is taking two steps Undetermined / Future。
9. Collaboration mapping of drug discovery and DDS
10. Technologies, Products and Services
| Technology | Typical Products and Initiatives | Stage |
|---|---|---|
| Mono nal Antibody | Dupixent (in)ts IL-4 and IL-13 routes), Beyfortus (infant RSV prevention, long-acting type), and Sarclisa (with subcutaneous injections) | Approved |
| Nanobody (VHH) | Cablivi (TNFα×OX40L) | Approved / Phase 3 / Phase 2 |
| Fc Fusion Protein | ALIIIIIIO (VIII factor, 1 week), Eloctate, Alprolix, which combines Fc, VWF fragments and XTEN. Collaboration with Sobi | Approved |
| siRNA | Qfitlia. One subcutaneous injection in two months with Alnylam’s ESC-GalNAc binding technology. Prefilled pen | U.S. approval (March 28, 2025), approved in China, etc. |
| mRNA vac m | SP0256(RSV+hMPV), SP0289(H), SP0268(Acne), SP0269(Clamydia), SP0291 | Phase 1-2 |
| AAV Therapy | SAR402663, SAR446597, SAR446268 | Contact Us |
| ADC | ADC with Topoisomerase I in)tor targeting CEACAM5 | Contact Us |
| AI for manufacturing | SimpLY Used in anticoagulants manufacturing in France and Singapore | In operation |
In one company, Sanofi has a completely different material and process requirements. siRNA Qfitlia is as specified by 20-FGalNAc (N-acetyl galactosamine)Designed to achieve subcutaneous injections twice a month FactsHome This is the chemical modification of nucleic acid and the GalNAc conjugates. It does not use lipids such as LNP. mRNA vaccine is generallyLipid nanoparticles (LNP)In order to be wrapped and delivered, lipid materials such as ionized lipids are effective (explanation). The composition of LNP in sanofy is non-dis。sure).
ALIIIIIIO is called XTEN in protein.Hydrophilic Polypeptide Chainto extend the time to stay in the blood FactsHome This is a way to realize the same goal as polyethylene glycol (PEG) modifiers in an array incorporating genes instead of chemical modifiers (explanation). 20-F describes the production of cell culture, microorganism culture, and viral vectors for bio-manufacturing hubs. Treat all chemical compounds, microbial culture, cell culture, virus vector, and lipid preparations with one factory network.It is also the characteristics and difficulty of this company. Undetermined / Future。
11. Risks that this company has
| Risks | ||
|---|---|---|
| Dependency on Dupixent | About 36% of the sales are Dupixent and jointly with Regeneron. Depending on the business execution of the partner, it is described in 20-F | Facts |
| The possibility that mRNA does not produce results | "MRNA technology is still in the early stages", "the possibility that translate bio acquisition does not produce expected results" and 20-F | Facts |
| Late development failure | Reduced €1.663 billion in Trebrutinib (2025). Discovered phase 3 of coli vaccine candidate. | Facts |
| Integrated risk of acquisition | The possibility that the acquisition of Blueprint does not produce the expected benefits, and the integration cost is swelling | Facts |
| Complexity of manufacturing | The production of biologics and vac s requires special equipment, certified human resources and special raw materials. | Facts |
| Vac Market Competition | When new entry is expected such as mixing mRNA alone or RNA with COVID-19, it is described in 20-F | Facts |
| Dispersion of manufacturing technology | It is necessary to have different manufacturing technology for each modalities, and it is difficult to scale with any one |
12. Glossary
- Mono nal Antibody
- Antibody drugs that recognize only one type of antigen. Produced by cell culture.
- Nanobody (VHH)
- Small antibody fragments that are made only by the variable part of the heavy chain, antibody from the antibody. Multi-targeting is easy to connect.
- Fc Fusion Protein
- The Fc portion of the antibody is connected to the protein to extend the time to stay in the blood.
- XTEN
- Hydrophilic amino acid sequence that blends with protein. Increase the size of the appearance and slow the discharge from the kidneys.
- siRNA
- Nucleic acid drugs that suppress the production of certain proteins with short two-strand RNA.
- GalNAc binding
- A technology to deliver sugar (GalNAc) that binds to the receptor of hepatocellular cells to the liver.
- mRNA vac m
- A vac that delivers mRNA to the body, which is a design diagram of antigen, and creates antigens to cells.
- LNP
- Particulates made of fat that are wrapped in mRNA and delivered to cells.
- AAV Therapy
- How to deliver the。eutic genes to cells as a carrier of the adenos accompanying virus.
- ADC
- Antibody drug complex. Connect the drug to antibody with a linker and deliver it to targeted cells.
- BARDA
- Department of Bio。 Research and Development, Department of Health and Welfare Fund development of pandemic measures.
- Form 20-F／6-K
- Annual reports and reports from time to time that foreign companies listed in the US submit to SEC.
Concept diagram of AI generation13. Source
- Sanofi Form 20-F for the) year ended December 31, 2025 Strategy, AI Initiatives, Acquisition and Introduction of 2025, Product Description (Dupixent, Qfitlia, Cabbl , ALIIIIIIO, Beyfortus), Pipeline, Manufacturing Bases and Equipment Investment, R&D and Personnel, Number of , Listed Markets, Losses, Risk Factors https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm
- Sanofi 2026 Half-year management report Sales, Dupixent sales, R&D and capital investment in January and June 2026, completion of acquisition of Dynavax, approval status,。. https://www.sec.gov/Archives/edgar/data/1121404/000162828026050803/exhibit992-2026halfyearman.htm
- Sanofi Qfitlia approved first therapy in the US to treat hemophilia A or B with or without in)tors FDA approval, siRNA, ATLAS test configuration and NCT number. https://www.sanofi.com/en/media-room/press-releases/2025/2025-03-28-20-07-38-3051637
- Sanofi Vac)s and theticseutics (September 14, 2021) https://www.sanofi.com/en/media-room/press-releases/2021/2021-09-14-13-26-25-2296830
- Sanofi Official website (for confirmation of company profile and logo) https://www.sanofi.com/en
14. Response table of claims and sources
| Content | ||
|---|---|---|
| Official name, head office location, listed market (Euro t Paris, Nasdaq) | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm |
| Sales, Dupixent sales, R&D expenses (18.0%) for 2024-2025, capital investment, number of employees, R&D personnel 9,274 | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm |
| Dupixent is about 36.0% of sales, about 12.4% of R&D personnel, and the number of employees in 2024 (reverse) | The calculation of this paper | )ulation of this paper (cal)d from the number of source 1) https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm |
| Sales from January to June 2026, Dupixent sales, R&D expenses, capital investment, completion of Dynavax acquisition, approval of Sarclisa subcutaneous injection formulation | Facts | Source 2 https://www.sec.gov/Archives/edgar/data/1121404/000162828026050803/exhibit992-2026halfyearman.htm |
| Self-definition of "technology and manufacturing platform including mRNA" | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm |
| Evolutive Facility and New Plant in Singapore | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm |
| Acquisition and introduction of Ablynx, Blueprint, Vigil, Visbio, Dren Bio and Dynavax | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm |
| Translate Bio acquisition completed (September 14, 2021, $38, mRNA Center of Excellence) | Facts | Source 4 https://www.sanofi.com/en/media-room/press-releases/2021/2021-09-14-13-26-25-2296830 |
| Qfitlia’s U.S. approval (March 28, 2025), siRNA, ESC-GalNAc, once every two months | Facts | Source 1・3 https://www.sanofi.com/en/media-room/press-releases/2025/2025-03-28-20-07-38-3051637 |
| Cablivi・AL、IIIO・Beyfortus product description and approval time | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm |
| mRNA vaccine, nanobody, AAV, ADC stage and stage, BARDA funding | Facts | Source 1・2 https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm |
| AI Initiatives (Formation Bio, OpenAI, P, SimpLY and 10 million reduction estimates) | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm |
| Risk factors related to loss of Trebutinib, mRNA, acquisition and manufacturing | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm |
| Drug and DDS Classification | The calculation of this paper | This article does not specify the company name. The company name is an example from the series of companies in this article. |
| Research and development costs by modalities, composition, and procurement of LNPs, the ability of the Evolutive Facility, the application period of mRNA vacs, and the annual bleeding rates of Qfitlia. | Undetermined / Future | Unconfirmed in the first article or in this article. Don't guess https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm |
| Individual joint research with universities | Undetermined / Future | No individual description in Source 1. This article does not break even if it is not present https://www.sec.gov/Archives/edgar/data/1121404/000162828026008403/sny-20251231.htm |
| Comparison between GalNAc and LNP | Undetermined / Future | General technical commentary, not disclosure of specifications of the company |
| Read the double-targeted nanobody to the next pillar, mRNA reads the vac's first. | Interpret this paper from the pipeline of Source 1. | |
| New technology is a policy to quickly align with acquisition and introduction, and short-term two-stage preparation for the acquisition of late items | Interpret this paper from the 2025 pipeline changes and risk factors of Source 1. | |
| Risks caused by dispersion of manufacturing technology, difficulty handling various modalities with one factory network | Interpre of this paper from the description of the production base of Source 1 |
Last Updated:September 26, 2026/Troy Technical
All numbers in this document are based on the legal disclosure document submitted by Sanofi to the US Securities and Exchange Commission (SEC) and the official release of the company. We do not use estimates and media-based numbers of survey companies. The "、ulation" section is an interpretation that the article reads from the primary information and is not an announcement of the company. This article is not medical advice, but is not recommended to use certain drugs.